Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes

NCT01324505 · Completed

Last updated 2026-05-28

This clinical trial is testing how semaglutide affects the levels of ethinylestradiol in the bloodstream when taken with oral contraceptives in women who have type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 43 people

Who can join Ages 18+ · female only

Timeline Started 2011-03 · est. completion 2012-01

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT01324505 ↗

Description as written by the study sponsor.

This clinical trial is conducted in Europe. The purpose of the trial is to investigate the influence on the pharmacokinetics (the rate at which the trial drug is eliminated from the body) of an oral contraceptive combination drug after multiple administration of semaglutide in female subjects with type 2 diabetes.

Treatments tested

semaglutide Drug

Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
placebo Drug

Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
Microgyn® Drug

Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.

Main thing measured	Area under the ethinylestradiol concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01324505 ↗